Baricitinib, Corticosteroids, low-molecular weight heparin, and anticoagulants are covered to be used to COVID-19 confirmed patients.

Kaletra (Lopinavir + ritonavir), Hydroxychloroquine, and Ribavirin were decided to be removed from the benefit.

The MOHW decided to partially revise the notification of details on the application standards and methods of pharmaceutical benefits for drugs in order to properly apply insurance for COVID-19 treatment drugs. and announced on the 11th that it will inquire industry opinions.

The main goal of this amendment is to clearly define the target of confirmed patiens with COVID-19 in the COVID-19 treatment (general principle), and the main